Avadel Pharmaceuticals (AVDL) Debt to Equity: 2009-2021
Historic Debt to Equity for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to $1.82.
- Avadel Pharmaceuticals' Debt to Equity fell 862.71% to -$10.95 in Q3 2022 from the same period last year, while for Sep 2022 it was -$10.95, marking a year-over-year decrease of 862.71%. This contributed to the annual value of $1.82 for FY2021, which is 130.33% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Debt to Equity of $1.82 as of FY2021, which was up 130.33% from $0.79 recorded in FY2020.
- In the past 5 years, Avadel Pharmaceuticals' Debt to Equity ranged from a high of $45.03 in FY2018 and a low of -$4.36 during FY2019.
- Moreover, its 3-year median value for Debt to Equity was $0.79 (2020), whereas its average is -$0.58.
- Per our database at Business Quant, Avadel Pharmaceuticals' Debt to Equity surged by 3,795.22% in 2018 and then slumped by 109.68% in 2019.
- Avadel Pharmaceuticals' Debt to Equity (Yearly) stood at $1.16 in 2017, then soared by 3,795.22% to $45.03 in 2018, then plummeted by 109.68% to -$4.36 in 2019, then surged by 118.13% to $0.79 in 2020, then surged by 130.33% to $1.82 in 2021.